Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.ONC · Entity 2168 | Director · Chair, Scientific Advisory Brd | October 13, 2026 | October 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date October 13, 2026 · Filed October 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2026-10-13 transaction · row 10
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 5 · 2026-10-13 · Exercise / conversion · Acquired 31,027 · Balance 31,027 F4: Each American Depositary Share represents 13 Ordinary Shares. Row 6 · 2026-10-13 · Sale · Disposed 7,167 · Balance 23,860 F4: Each American Depositary Share represents 13 Ordinary Shares. F5: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.98 to $349.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 7 · 2026-10-13 · Sale · Disposed 10,361 · Balance 13,499 F4: Each American Depositary Share represents 13 Ordinary Shares. F5: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $349.98 to $350.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 8 · 2026-10-13 · Sale · Disposed 5,681 · Balance 7,818 F4: Each American Depositary Share represents 13 Ordinary Shares. F5: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.98 to $351.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 9 · 2026-10-13 · Sale · Disposed 6,558 · Balance 1,260 F4: Each American Depositary Share represents 13 Ordinary Shares. F5: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.99 to $352.95, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 10 · 2026-10-13 · Sale · Disposed 1,260 · Balance 0 F4: Each American Depositary Share represents 13 Ordinary Shares. F5: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.01 to $353.325, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2026-11-15 | Direct | 403,364 |
Reported balance
After 2026-10-13 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-10-13 · Exercise / conversion · Disposed 403,351 · Balance 403,364 F11: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F12: These securities vest over a four-year period as follows: 25% on July 13, 2017, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 4,588,113 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,588,113 |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 1,025,063 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,025,063 F1: These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 3,953,100 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,953,100 F2: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interests are owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 50 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 50 F3: These securities are held by the spouse of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership.
F2: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interests are owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.
F3: These securities are held by the spouse of the Reporting Person.
F4: Each American Depositary Share represents 13 Ordinary Shares.
F5: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.98 to $349.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $349.98 to $350.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.98 to $351.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.99 to $352.95, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.01 to $353.325, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F11: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.
F12: These securities vest over a four-year period as follows: 25% on July 13, 2017, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2026 Filed Oct 15, 2026 21:08 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 403,351 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001662982-26-000006 · wk-form4_1792098516.xml · derivative · entry 11 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 403,364 Underlying: Ordinary Shares · 403,351 shares Expires 2026-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F12 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on July 13, 2017, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| October 13, 2026 Filed Oct 15, 2026 21:08 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 1,260 | $353.24 | $445,078.24 |
DisclosureSEC source: 0001662982-26-000006 · wk-form4_1792098516.xml · nonDerivative · entry 10 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.01 to $353.325, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| October 13, 2026 Filed Oct 15, 2026 21:08 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 6,558 | $352.57 | $2,312,148.16 |
DisclosureSEC source: 0001662982-26-000006 · wk-form4_1792098516.xml · nonDerivative · entry 9 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,260 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.99 to $352.95, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| October 13, 2026 Filed Oct 15, 2026 21:08 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 5,681 | $351.40 | $1,996,279.54 |
DisclosureSEC source: 0001662982-26-000006 · wk-form4_1792098516.xml · nonDerivative · entry 8 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,818 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.98 to $351.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| October 13, 2026 Filed Oct 15, 2026 21:08 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 10,361 | $350.47 | $3,631,262.15 |
DisclosureSEC source: 0001662982-26-000006 · wk-form4_1792098516.xml · nonDerivative · entry 7 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,499 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $349.98 to $350.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| October 13, 2026 Filed Oct 15, 2026 21:08 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 7,167 | $349.56 | $2,505,305.84 |
DisclosureSEC source: 0001662982-26-000006 · wk-form4_1792098516.xml · nonDerivative · entry 6 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,860 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.98 to $349.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| October 13, 2026 Filed Oct 15, 2026 21:08 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 31,027 | $36.90 | $1,144,896.30 |
DisclosureSEC source: 0001662982-26-000006 · wk-form4_1792098516.xml · nonDerivative · entry 5 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 01:11 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 403,364 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · derivative · entry 16 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 806,715 Underlying: Ordinary Shares · 403,364 shares Expires 2026-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F16 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on July 13, 2017, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 01:11 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 738 | $367.23 | $271,012.20 |
DisclosureSEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 15 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $367.13 to $367.25, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 01:11 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 14,525 | $366.58 | $5,324,549.81 |
DisclosureSEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 14 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 738 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.13 to $367.12, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 01:11 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 2,047 | $365.85 | $748,890.65 |
DisclosureSEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 13 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,263 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $365.13 to $366.12, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 01:11 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 3,419 | $364.07 | $1,244,746.78 |
DisclosureSEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 12 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,310 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.67 to $364.62, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 01:11 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 3,499 | $363.10 | $1,270,485.15 |
DisclosureSEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 11 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,729 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.67 to $363.59, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 01:11 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 4,239 | $362.17 | $1,535,228.03 |
DisclosureSEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 10 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,228 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $361.66 to $362.65, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 01:11 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 2,241 | $361.05 | $809,119.55 |
DisclosureSEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 9 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,467 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.65 to $361.64, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 01:11 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 40 | $359.16 | $14,366.40 |
DisclosureSEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 8 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,708 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 01:11 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 120 | $358.71 | $43,044.80 |
DisclosureSEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 7 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,748 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.11 to $359.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 01:11 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 160 | $356.97 | $57,114.59 |
DisclosureSEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 6 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,868 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.94 to $357.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 01:11 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 31,028 | $36.90 | $1,144,933.20 |
DisclosureSEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 5 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:49 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 403,351 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · derivative · entry 14 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,210,079 Underlying: Ordinary Shares · 403,351 shares Expires 2026-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F15 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on July 13, 2017, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:49 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 6,278 | $351.25 | $2,205,173.87 |
DisclosureSEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 13 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.82 to $351.74, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:49 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 6,569 | $350.27 | $2,300,950.56 |
DisclosureSEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 12 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,278 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $349.81 to $350.80, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:49 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 10,688 | $349.28 | $3,733,140.98 |
DisclosureSEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 11 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,847 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.80 to $349.74, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:49 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 7,492 | $348.31 | $2,609,572.98 |
DisclosureSEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 10 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,535 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.07 to $348.79, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:49 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 31,027 | $36.90 | $1,144,896.30 |
DisclosureSEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 9 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:49 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 1,721 | $348.01 | $598,929.68 |
DisclosureSEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 8 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $347.80 to $348.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:49 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 1,517 | $347.39 | $526,992.91 |
DisclosureSEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 7 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,721 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $346.79 to $347.78, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:49 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 2,841 | $346.16 | $983,433.46 |
DisclosureSEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 6 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,238 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $345.71 to $346.70, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:49 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 1,181 | $345.38 | $407,897.32 |
DisclosureSEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 5 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,079 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $344.71 to $345.66, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:54 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 193,492 | $0.00 Strike: $20.81 | $0.00 |
DisclosureSEC source: 0001662982-26-000001 · wk-form4_1781560491.xml · derivative · entry 5 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,492 Underlying: Ordinary Shares · 193,492 shares Expires 2036-06-10 F5 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F5 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F6 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 11, 2026 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:54 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GrantOrdinary Shares | 99,892 | $0.00 | $0.00 |
DisclosureSEC source: 0001662982-26-000001 · wk-form4_1781560491.xml · nonDerivative · entry 1 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,682,493 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 11, 2026, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:47 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GiftOrdinary Shares | 424,073 | $0.00 | $0.00 |
DisclosureSEC source: 0001662982-25-000003 · wk-form4_1762984017.xml · nonDerivative · entry 1 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,582,601 F1 · price: Bona fide gift(s) of shares which are exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 21:12 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GiftOrdinary Shares | 148,096 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-25-000143 · wk-form4_1757625130.xml · nonDerivative · entry 1 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,006,674 F1 · price: Bona fide gift(s) of shares which are exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. Read SEC document |
| June 24, 2025 Filed Jun 25, 2025 21:08 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 100 | $267.81 | $26,781.00 |
DisclosureSEC source: 0001651308-25-000116 · wk-form4_1750885680.xml · nonDerivative · entry 8 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024. Read SEC document |
| June 24, 2025 Filed Jun 25, 2025 21:08 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 507 | $266.57 | $135,148.61 |
DisclosureSEC source: 0001651308-25-000116 · wk-form4_1750885680.xml · nonDerivative · entry 7 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.27 to $266.95, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 24, 2025 Filed Jun 25, 2025 21:08 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 1,100 | $265.35 | $291,887.75 |
DisclosureSEC source: 0001651308-25-000116 · wk-form4_1750885680.xml · nonDerivative · entry 6 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 607 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.02 to $265.86, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 24, 2025 Filed Jun 25, 2025 21:08 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 300 | $263.50 | $79,050.00 |
DisclosureSEC source: 0001651308-25-000116 · wk-form4_1750885680.xml · nonDerivative · entry 5 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,707 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.40 to $263.55, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:39 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 542,880 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001651308-25-000105 · wk-form4_1749764371.xml · derivative · entry 12 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7 Underlying: Ordinary Shares · 542,880 shares Expires 2025-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: These securities vest over a five-year period as follows: 20% on July 19, 2016, and the remaining in 48 successive equal monthly installments, subject to continued service. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:39 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 185,796 | $0.00 Strike: $20.26 | $0.00 |
DisclosureSEC source: 0001651308-25-000105 · wk-form4_1749764371.xml · derivative · entry 11 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,796 Underlying: Ordinary Shares · 185,796 shares Expires 2035-06-09 F11 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F11 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F12 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 10, 2025 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:39 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 100 | $264.85 | $26,485.00 |
DisclosureSEC source: 0001651308-25-000105 · wk-form4_1749764371.xml · nonDerivative · entry 10 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:39 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 6,787 | $264.08 | $1,792,313.67 |
DisclosureSEC source: 0001651308-25-000105 · wk-form4_1749764371.xml · nonDerivative · entry 9 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.66 to $264.65, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:39 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 16,094 | $263.17 | $4,235,501.43 |
DisclosureSEC source: 0001651308-25-000105 · wk-form4_1749764371.xml · nonDerivative · entry 8 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,887 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $262.66 to $263.65, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:39 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 15,878 | $262.20 | $4,163,262.41 |
DisclosureSEC source: 0001651308-25-000105 · wk-form4_1749764371.xml · nonDerivative · entry 7 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,981 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.66 to $262.65, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:39 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 2,901 | $261.20 | $757,753.09 |
DisclosureSEC source: 0001651308-25-000105 · wk-form4_1749764371.xml · nonDerivative · entry 6 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,859 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.66 to $261.64, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:39 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 41,760 | $6.50 | $271,440.00 |
DisclosureSEC source: 0001651308-25-000105 · wk-form4_1749764371.xml · nonDerivative · entry 5 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:39 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GrantOrdinary Shares | 98,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-25-000105 · wk-form4_1749764371.xml · nonDerivative · entry 1 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,180,861 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 10, 2025, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| May 13, 2025 Filed May 15, 2025 21:37 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 542,880 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001651308-25-000080 · wk-form4_1747345071.xml · derivative · entry 10 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 542,887 Underlying: Ordinary Shares · 542,880 shares Expires 2025-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: These securities vest over a five-year period as follows: 20% on July 19, 2016, and the remaining in 48 successive equal monthly installments, subject to continued service. The expiration date of the share option is July 19, 2025. Read SEC document |
| May 13, 2025 Filed May 15, 2025 21:37 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 200 | $225.68 | $45,136.00 |
DisclosureSEC source: 0001651308-25-000080 · wk-form4_1747345071.xml · nonDerivative · entry 9 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024. Read SEC document |
| May 13, 2025 Filed May 15, 2025 21:37 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 10,104 | $224.32 | $2,266,542.42 |
DisclosureSEC source: 0001651308-25-000080 · wk-form4_1747345071.xml · nonDerivative · entry 8 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.03 to $224.77, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| May 13, 2025 Filed May 15, 2025 21:37 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 21,235 | $223.41 | $4,744,092.24 |
DisclosureSEC source: 0001651308-25-000080 · wk-form4_1747345071.xml · nonDerivative · entry 7 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,304 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.03 to $224.02, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.